The influence of levodopa-induced dyskinesias on manual tracking in patients with Parkinson's disease

被引:19
|
作者
Lemieux, Sarah
Ghassemi, Mehrdad
Jog, Mandar
Edwards, Roderick
Duval, Christian
机构
[1] Univ Quebec, Dept Kinanthropol, Montreal, PQ H3C 3P8, Canada
[2] Brock Univ, Fac Appl Hlth Sci, St Catharines, ON L2S 3A1, Canada
[3] Univ Western Ontario, London Hlth Sci Ctr, London, ON, Canada
[4] Univ Victoria, Dept Math & Stat, Victoria, BC, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
dyskinesia; Parkinson; kinematic; treatment; levodopa; bradykinesia; manual tracking; motor overflow;
D O I
10.1007/s00221-006-0632-2
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The influence of peak-dose, levodopa-induced dyskinesias (LID) on manual tracking (MT) was examined in 10 dyskinetic patients with Parkinson's disease (DPD), and compared to 10 age/gender-matched non-dyskinetic patients with Parkinson's disease (NDPD) and 10 healthy controls. Whole-body movement (WBM) and MT performance were recorded simultaneously with a 6-degrees-of-freedom magnetic motion tracker and forearm rotation sensors, respectively. Subjects were asked to match the length of a computer-generated line with a line they controlled via wrist rotation. Results show that DPD patients had greater WBM magnitude at rest and during the motor task, both in displacement and in velocity. All groups displayed some increase in WBM displacement from rest to MT, but only the DPD group had a significant increase in WBM velocity during movement. As for MT performance (determined by assessing the positional mismatch between subjects' and target lines), ERROR in displacement was statistically similar between groups. There was no correlation between ERROR and the magnitude of WBM within the DPD group. The DPD group showed significant increased ERROR when the velocity of the subject's line was compared with that of the velocity of the target line. When two distinct target pace segments were examined (FAST/SLOW), no significant differences were found in ERROR for displacement for either group, but both the NDPD and DPD group showed increased ERROR from SLOW to FAST for velocity. This was accompanied with an increase in WBM velocity only in the DPD group. The lack of increased ERROR during the SLOW tracking portion in the DPD group supports the notion that the dyskinesias themselves were not primarily responsible for the ERROR seen in the patients. When examining the positive or negative values of ERROR (i.e., faster or slower than the target), we found that the increased ERROR in velocity observed in the DPD group was the result of excess velocity rather than bradykinesia, manifested as isolated deviations from the target trace in the DPD group that were coherent in time with increased ERROR in velocity. In conclusion, evidence presented in the present study shows that the LID was not the primary cause of the ERROR seen in the DPD group. Accordingly, we propose that the increased ERROR seen in the DPD group resulted from a mechanism distinct from the one generating LID.
引用
收藏
页码:465 / 475
页数:11
相关论文
共 50 条
  • [31] The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease
    Rascol, O
    JOURNAL OF NEUROLOGY, 2000, 247 : 51 - 57
  • [32] Endocannabinoid levels in patients with Parkinson's disease with and without levodopa-induced dyskinesias
    Marchioni, Camila
    Santos-Lobato, Bruno Lopes
    Costa Queiroz, Maria Eugenia
    Crippa, Jose Alexandre S.
    Tumas, Vitor
    JOURNAL OF NEURAL TRANSMISSION, 2020, 127 (10) : 1359 - 1367
  • [33] Endocannabinoid levels in patients with Parkinson’s disease with and without levodopa-induced dyskinesias
    Camila Marchioni
    Bruno Lopes Santos-Lobato
    Maria Eugênia Costa Queiroz
    José Alexandre S. Crippa
    Vitor Tumas
    Journal of Neural Transmission, 2020, 127 : 1359 - 1367
  • [34] Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease
    Alonso-Frech, F.
    Zamarbide, I.
    Alegre, M.
    Rodriguez-Oroz, M. C.
    Guridi, J.
    Manrique, M.
    Valencia, M.
    Artieda, J.
    Obeso, J. A.
    BRAIN, 2006, 129 : 1748 - 1757
  • [35] Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias
    Morgante, F
    Espay, AJ
    Gunraj, C
    Lang, AE
    Chen, R
    BRAIN, 2006, 129 : 1059 - 1069
  • [36] Amantadine for the treatment of levodopa-induced dyskinesias in Parkinson's disease.
    Cersosimo, MG
    Scorticati, MC
    Micheli, FE
    MEDICINA-BUENOS AIRES, 2000, 60 (03) : 321 - 325
  • [37] Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias
    Piccini, P
    Weeks, RA
    Brooks, DJ
    ANNALS OF NEUROLOGY, 1997, 42 (05) : 720 - 726
  • [38] The effect of subthalamic nucleus stimulation on levodopa-induced dyskinesias in patients with Parkinson's disease
    Fraix, V
    Pollak, P
    Van Blercom, N
    Xie, J
    Krack, P
    Benabid, AL
    NEUROLOGY, 1999, 52 (06) : A403 - A404
  • [39] The Motor Inhibition System in Parkinson's Disease With Levodopa-Induced Dyskinesias
    Cerasa, Antonio
    Donzuso, Giulia
    Morelli, Maurizio
    Mangone, Graziella
    Salsone, Maria
    Passamonti, Luca
    Augimeri, Antonio
    Arabia, Gennarina
    Quattrone, Aldo
    MOVEMENT DISORDERS, 2015, 30 (14) : 1912 - 1920
  • [40] Clinical Features, Pathophysiology, and Treatment of Levodopa-Induced Dyskinesias in Parkinson's Disease
    Guridi, J.
    Gonzalez-Redondo, R.
    Obeso, J. A.
    PARKINSONS DISEASE, 2012, 2012